UK Markets close in 2 hrs 47 mins

Akebia Therapeutics, Inc. (AKBA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.3302-0.0158 (-4.57%)
At close: 04:00PM EDT
Sign in to post a message.
  • H
    HABERLY
    AKBA looks like it is about to drop. Be careful guys. I have been reading (http://Achieverspot.tech) and their stocks have been doing way better.
  • A
    Anonymous
    AKBA
    -6.3144%

    OTSKY
    +1.64%
    Vandana Singh
    Mon, May 16, 2022, 2:13 PM
    In this article:

    AKBA
    -6.3144%

    OTSKY
    +1.64%

    Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat.

    Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated.

    Akebia said in an SEC filing filed Friday that the termination will go into effect in a year.
  • d
    dj
    As we call for resignation, it’s pretty clear that the company is indifferent. No communication giving any direction as the stock continues to slide into oblivion. They need someone in charge who can get out in front of some of the stuff that is happening to them… not just sit there and take it
  • M
    Mizo
    Net cashflow increased $34.6 million from last quarter.
    Now cash on hands stand at $174.6 millions.
  • t
    tpstrong21
    this is what happens when big pharma doesnt bring a block buster to market in the USA, works just fine in Japan for year, but here? NOPE.....so much corruption
  • N
    Nanostylo
    Vifor gave additional Dollars in February, that might have caused a conflict with OTSUKA...Nonetheless it is quite funny to see such price reaction as in fact, VAD is already off the table with regard to market cap. So these are funny games as someone wants the whole cake for a cheap Dolllar
  • A
    Anonymous
    how can 1 ceo ruin 2 companies kerx and akba and stiil in charge..something not right
  • d
    dj
    Just voted for the upcoming meeting. Not that it will matter (with my small amount of shares) but I voted against everything but the accounting firm. Because it seemed like the best way to vote no confidence without selling my shares.
  • A
    Andre
    people who put their money in this stock deserve to lose all their money, do you DD
  • J
    Jeff
    The Otsuka partnership ending was the final nail in the coffin.

    I wonder where Butler will end up. Hopefully unemployed.

    The open class action lawsuits are meaningless. Butler raped KERX and AKEBA shareholders for years.

    There is nothing left.
  • G
    GAN
    Kind Attn: Board of Directors, Akebia

    At this juncture the Company’s financial condition is in a serious doldrums due to inefficiency in the marketing of the Sole Product and also incurring huge financial expenditure with the proposed Vadasustat launch. We shareholders wonder ‘why anyone in the Management or the Board’ thought of a case where ‘FDA denying the Vadasustat approval?’. It is a 150 mln $ question and so far none of the Senior Management and the Board has taken the moral responsibility and ownership for this debacle. Rather poor low level employees were victimized made as scape goat and let go.

    This lack of preparedness for such an eventuality has put the Company in a Bankrupt situation. 

    The Senior Management not only ‘ don’t have the Managerial skill sets to run the operations profitably but also didn’t possess the necessary Listening skills to interpret the FDA input with multiple meetings’. Definitely FDA didn’t provide you any verbal or written assurances that they will approve Vadasustat for any of the conditions, under these circumstances going ahead for Launch preparedness was a serious mistake and costs the company over $150 million. 

    It is time for he Board to seriously consider putting up the company for ‘Sale’ rather than messing around further and destroying the valuation further and further. Any dilution and share issuance will only allow few month of survival and will not revive the company much longer.

    Thanking you,

    Yours truly,
  • G
    GAN
    For all who those sold stock also

    Please help us to vote against the resolutions to unseat Butler.

    Gl!
  • G
    GAN
    Hope all shareholders vote not to nominate Butler
  • C
    CC
    100% out of AKBA. Held this stock since 2014 and for my patience I was rewarded with losses amounting to just over $50k. Thanks, Butler. Not touching a biotech ever again. For now, I'm going more disciplined and will focus on singles and doubles instead of the metaphorical home run swing. Stuck out hard on this one.

    I wish you all the best.
  • G
    GAN
    Still holding onto my shares with a possibility if Japanese partners buying them out to take control of the entire company. $2 is the price I’m expecting.

    Gl!
  • K
    Khaja
    The FDA does this often to Biotech companies and should not have been a surprise to AKBA . The drug does work and there is a path to approval , im still a holder of the shares .
  • Z
    Zard
    Woohoo. ATL!!!
    Congrats to the CEO and BOD for doing such a great job.
    Let give each other a bit more bonuses for the job well done.
  • K
    Krimo
    Less than two weeks from now we will touch $1.
    I just know it. Start counting now
  • J
    JUAN
    Hi guys! Do we all still agree on that $12 price target? Too ambitious?
  • A
    Anonymous
    Need buyout soon
    Target-$3-5